ProMIS Neurosciences
15 hedge funds and large institutions have $3.85M invested in ProMIS Neurosciences in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
6,468% more capital inflows, than outflows
Capital inflows: $825K | Capital outflows: $12.6K
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
7% more funds holding
Funds holding: 14 → 15 (+1)
2.59% more ownership
Funds ownership: 15.14% → 17.73% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ally Bridge Group
New York
|
+$800K |
| 2 |
Kingsview Wealth Management
Grants Pass,
Oregon
|
+$16.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IEQ Capital
Foster City,
California
|
-$12.6K |
PMN Hedge Fund Activity: Q4 2023 in Review
15 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in ProMIS Neurosciences (PMN) for Q4 2023, worth a combined $3.85M — down 31% from $5.61M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PMN positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Ally Bridge Group, adding an estimated $800K. The largest seller was IEQ Capital, cutting an estimated $12.6K.
- 15 institutional investors held ProMIS Neurosciences (PMN) as of Q4 2023, up from 14 in Q3 2023.
- Funds reported $3.85M of ProMIS Neurosciences stock for Q4 2023, down 31% quarter-over-quarter.
- 1 fund opened new ProMIS Neurosciences positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest ProMIS Neurosciences buyer in Q4 2023 was Ally Bridge Group, an estimated $800K added.
- The largest ProMIS Neurosciences seller in Q4 2023 was IEQ Capital, an estimated $12.6K sold.
Based on aggregated 13F filings for Q4 2023.